EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment

Mark J Butler iD, Thevaa Chandereng iD, Heejoon Ahn iD, Stefani Slotnick iD, Danielle Miller iD, Alexandra Perrin iD, Jordyn Rodillas iD, Ciaran P Friel iD, Ashley M Goodwin iD, Ying Kuen Cheung iD, Karina W Davidson iD

JMIR Formative Research · 2025

DOI: 10.2196/58192 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Formative Research, 2025. Verfasst von Mark J Butler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042-1069, United States, 1 6467667181. Hauptthemen laut MEDLINE: Melatonin, Dietary Supplements, Sleep Initiation and Maintenance Disorders, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogenous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient.

Objective

This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep.

Methods

This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0 mg and 0.5 mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial comprised a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker [Google]) and sleep quality (measured using the consensus sleep diary).

Results

Participants rated the usability of the personalized trial as acceptable (average SUS score 76.3, SD 17.1), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0 mg and 0.5 mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0 mg ( P =.70) and 0.5 mg ( P =.90) melatonin intervention periods and the baseline period. In addition, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality.

Conclusions

Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Furthermore, the treatment effects’ lack of heterogeneity among participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninDietary SupplementsSleep Initiation and Maintenance DisordersPrecision MedicineHumansCross-Over StudiesMaleFemaleFeasibility StudiesMiddle AgedAdultTreatment OutcomeAgedSleepSleep QualityPatient Satisfaction

Stichwörter der Autor:innen

FitbitN-of-1effectivenessfeasibilityheterogeneityinterventionmelatoninpersonalizedpersonalized trialplacebopoor sleeprandomized crossover trialsleep durationsleep healthsleep quality

Substanzen

Melatonin

Autor:innen und Institutionen

  • Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042-1069, United States, 1 6467667181.
  • Institute of Health System Science, Feinstein Institutes For Medical Research, Manhasset, NY, United States.
  • Mailman School of Public Health, Columbia University, New York, NY, United States.

ORCID-Profile: Mark J Butler, Thevaa Chandereng, Heejoon Ahn, Stefani Slotnick, Danielle Miller, Alexandra Perrin, Jordyn Rodillas, Ciaran P Friel, Ashley M Goodwin, Ying Kuen Cheung, Karina W Davidson

Förderung

  • NIH HHS

Zitieren

APA

Butler, M. J., Chandereng, T., Ahn, H., Slotnick, S., Miller, D., Perrin, A., Rodillas, J., Friel, C. P., Goodwin, A. M., Cheung, Y. K., & Davidson, K. W. (2025). A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment. JMIR Formative Research. https://doi.org/10.2196/58192

Vancouver

Butler MJ, Chandereng T, Ahn H, Slotnick S, Miller D, Perrin A, et al. A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment. JMIR Formative Research. 2025. doi:10.2196/58192

BibTeX
@article{Butler2025,
  author = {Butler, Mark J and Chandereng, Thevaa and Ahn, Heejoon and Slotnick, Stefani and Miller, Danielle and Perrin, Alexandra and Rodillas, Jordyn and Friel, Ciaran P and Goodwin, Ashley M and Cheung, Ying Kuen and Davidson, Karina W},
  title = {A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment},
  journal = {JMIR Formative Research},
  year = {2025},
  doi = {10.2196/58192}
}
Kostenlos starten →